Long-Term Safety and Efficacy of Fremanezumab for the Prevention of Cluster Headache

Study Title
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
Teva Identifier
TV48125-CNS-30058 | 2016-003172-43
ClinicalTrials.gov Identifier
NCT03107052
Study Status
Terminated
Trial Condition(s)
Cluster Headache
Interventions
Drug: Fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
April 27, 2017 - June 11, 2019
Phase
Phase 3

Additional info

Study Type

Interventional